Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes

Graham, 2013, Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans, Circ Res, 112, 1479, 10.1161/CIRCRESAHA.111.300367 Hewing, 2013, Rapid regression of atherosclerosis with MTP inhibitor treatment, Atherosclerosis, 227, 125, 10.1016/j.atherosclerosis.2012.12.026 Hussain, 2008, Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism, Curr Opin Lipidol, 19, 277, 10.1097/MOL.0b013e3282feea85 Aegerion Pharmaceuticals, Inc. Sundaram, 2012, Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion, Arterioscler Thromb Vasc Biol, 32, 1073, 10.1161/ATVBAHA.111.241455 Yao, 2012, Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production, Curr Opin Lipidol, 23, 206, 10.1097/MOL.0b013e328352dc70 Furtado, 2012, Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins, J Lipid Res, 53, 784, 10.1194/jlr.P021717 Samaha, 2008, Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia, Nat Clin Pract Cardiovasc Med, 5, 497, 10.1038/ncpcardio1250 Goldstein, 2009, The LDL receptor, Arterioscler Thromb Vasc Biol, 29, 431, 10.1161/ATVBAHA.108.179564 Brown, 2009, Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL, J Lipid Res, 50, S15, 10.1194/jlr.R800054-JLR200 Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J Biol Chem, 279, 50630, 10.1074/jbc.M410077200 Peterson, 2008, PCSK9 function and physiology, J Lipid Res, 49, 1152, 10.1194/jlr.E800008-JLR200 Steinberg, 2009, Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels, Proc Natl Acad Sci U S A, 106, 9546, 10.1073/pnas.0904560106 Timmins, 2005, Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I, J Clin Invest, 115, 1333, 10.1172/JCI200523915 Wang, 2007, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo., J Clin Invest, 117, 2216, 10.1172/JCI32057 Brooks, 1999, The dark side of sexual selection, Trends Ecol Evol, 14, 336, 10.1016/S0169-5347(99)01689-4 Orso, 2000, Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice, Nat Genet, 24, 192, 10.1038/72869 Knox Klett, 2003, Genetic defenses against noncholesterol sterols, Curr Opin Lipidol, 14, 341, 10.1097/00041433-200308000-00001 Altmann, 2004, Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption, Science, 303, 1201, 10.1126/science.1093131 Garcia-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1), Proc Natl Acad Sci U S A, 102, 8132, 10.1073/pnas.0500269102 Grigore, 2008, Combination therapy in cholesterol reduction: focus on ezetimibe and statins, Vasc Health Risk Manag, 4, 267 Burnett, 2007, MTP inhibition as a treatment for dyslipidemias: time to deliver or empty promises?, Expert Opin Ther Targets, 11, 181, 10.1517/14728222.11.2.181 Hesse, 2014, Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly, J Lipid Res, 55, 41, 10.1194/jlr.M040089 Jones, 2003, Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders, Nat Genet, 34, 29, 10.1038/ng1145 Young, 2011, GPIHBP1, an endothelial cell transporter for lipoprotein lipase, J Lipid Res, 52, 1869, 10.1194/jlr.R018689 Brunzell, 2001, Familial lipoprotein lipase deficiency, apoCII deficiency, and hepatic lipase deficiency, 2789 Sundaram, 2010, Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion, Nutr Metab (Lond), 7, 35, 10.1186/1743-7075-7-35 Adiels, 2005, Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia, Arterioscler Thromb Vasc Biol, 25, 1697, 10.1161/01.ATV.0000172689.53992.25 Gill, 2004, Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects, Atherosclerosis, 176, 49, 10.1016/j.atherosclerosis.2004.04.022 Wu, 2012, The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia, Curr Opin Lipidol, 23, 334, 10.1097/MOL.0b013e3283544424 Lafontan, 2009, Lipolysis and lipid mobilization in human adipose tissue, Prog Lipid Res, 48, 275, 10.1016/j.plipres.2009.05.001 Jiang, 2013, Lipoprotein metabolism in nonalcoholic fatty liver disease, J Biomed Res, 27, 1, 10.7555/JBR.27.20120077 Yao, 2013, Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion, Curr Opin Lipidol, 24, 160, 10.1097/MOL.0b013e32835aebe7 Myers, 2012, Challenges and opportunities of defining clinical leptin resistance, Cell Metab, 15, 150, 10.1016/j.cmet.2012.01.002 Löllmann, 1997, Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues, Biochem Biophys Res Commun, 238, 648, 10.1006/bbrc.1997.7205 Choi, 2010, Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway, Mol Cell Biol, 30, 5009, 10.1128/MCB.00797-10 Brown, 2008, Selective versus total insulin resistance: a pathogenic paradox, Cell Metab, 7, 95, 10.1016/j.cmet.2007.12.009 Kamagate, 2008, FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice, J Clin Invest, 118, 2347 Altomonte, 2004, Foxo1 mediates insulin action on apoC-III and triglyceride metabolism, J Clin Invest, 114, 1493, 10.1172/JCI200419992 Phung, 1997, Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum, J Biol Chem, 272, 30693, 10.1074/jbc.272.49.30693 Carvalheira, 2005, Cross-talk between the insulin and leptin signaling systems in rat hypothalamus, Obes Res, 13, 48, 10.1038/oby.2005.7 Andrews, 1999, Glucocorticoids and insulin resistance: old hormones, new targets, Clin Sci (Lond), 96, 513, 10.1042/CS19980388 Masuzaki, 2001, A transgenic model of visceral obesity and the metabolic syndrome, Science, 294, 2166, 10.1126/science.1066285 Guinane, 2013, Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ, Therap Adv Gastroenterol, 6, 295, 10.1177/1756283X13482996 Lee, 2006, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes, 55, 2256, 10.2337/db06-0006 Kim, 2009, Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity, Am J Physiol Endocrinol Metab, 296, E812, 10.1152/ajpendo.90710.2008 Chang, 2012, The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet, Lipids Health Dis, 11, 86, 10.1186/1476-511X-11-86 Hu, 2010, Berberine inhibits adipogenesis in high-fat diet-induced obesity mice, Fitoterapia, 81, 358, 10.1016/j.fitote.2009.10.010 Kong, 2004, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nat Med, 10, 1344, 10.1038/nm1135 Zhou, 2008, Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats, Biol Pharm Bull, 31, 1169, 10.1248/bpb.31.1169 Wu, 2011, Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia, Am J Physiol Regul Integr Comp Physiol, 300, R635, 10.1152/ajpregu.00441.2010 Yin, 2008, Efficacy of berberine in patients with type 2 diabetes mellitus, Metabolism, 57, 712, 10.1016/j.metabol.2008.01.013 Zhang, 2008, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine, J Clin Endocrinol Metab, 93, 2559, 10.1210/jc.2007-2404 Zhang, 2010, Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression, Metabolism, 59, 285, 10.1016/j.metabol.2009.07.029 Derosa, 2013, Effects of berberine on lipid profile in subjects with low cardiovascular risk, Expert Opin Biol Ther, 13, 475, 10.1517/14712598.2013.776037 Trimarco, 2011, Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet, Med J Nutrition Metab, 4, 133, 10.1007/s12349-010-0043-6 Ge, 2011, Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes, Int J Biol Sci, 7, 673, 10.7150/ijbs.7.673 Zhao, 2012, Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression, Diabetes, 61, 933, 10.2337/db11-1164 Zhou, 2010, Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes, Eur J Pharmacol, 649, 390, 10.1016/j.ejphar.2010.09.030 Li, 2009, Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine, J Biol Chem, 284, 28885, 10.1074/jbc.M109.052407 Abidi, 2005, Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine, Arterioscler Thromb Vasc Biol, 25, 2170, 10.1161/01.ATV.0000181761.16341.2b Lee, 2010, Anti-atherogenic effect of berberine on LXRα-ABCA1-dependent cholesterol efflux in macrophages, J Cell Biochem, 111, 104, 10.1002/jcb.22667 Li, 2011, Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver X receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters, Biol Pharm Bull, 34, 644, 10.1248/bpb.34.644 Chen, 2010, Berberine inhibits PTP1B activity and mimics insulin action, Biochem Biophys Res Commun, 397, 543, 10.1016/j.bbrc.2010.05.153 Cheng, 2006, Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK, Biochim Biophys Acta, 1760, 1682, 10.1016/j.bbagen.2006.09.007 Chang, 2010, Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, J Lipid Res, 51, 2504, 10.1194/jlr.M001958 Zhou, 2014, Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells, Fitoterapia, 92, 230, 10.1016/j.fitote.2013.11.010 Xie, 2011, Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice, PLoS One, 6, e24520, 10.1371/journal.pone.0024520 Zhang, 2012, Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats, PLoS One, 7, e42529, 10.1371/journal.pone.0042529 Koo, 2007, Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect, J Nutr Biochem, 18, 179, 10.1016/j.jnutbio.2006.12.005 Hayek, 1997, Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation, Arterioscler Thromb Vasc Biol, 17, 2744, 10.1161/01.ATV.17.11.2744 Allister, 2005, Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes, Diabetes, 54, 1676, 10.2337/diabetes.54.6.1676 Borradaile, 2003, Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation, Diabetes, 52, 2554, 10.2337/diabetes.52.10.2554 Mulvihill, 2009, Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance, Diabetes, 58, 2198, 10.2337/db09-0634 Nahmias, 2008, Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin, Hepatology, 47, 1437, 10.1002/hep.22197 Casaschi, 2002, Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase, Lipids, 37, 647, 10.1007/s11745-002-0945-8 Kurowska, 2004, Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin, Lipids, 39, 143, 10.1007/s11745-004-1212-8 Jang, 2008, Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters, Metabolism, 57, 1576, 10.1016/j.metabol.2008.06.014 Seo, 2008, Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice, Mol Nutr Food Res, 52, 995, 10.1002/mnfr.200700184 Li, 2010, Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats, Hepatology, 51, 1555, 10.1002/hep.23524 Kang, 2013, Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells, Eur Rev Med Pharmacol Sci, 17, 2578 Kim, 2010, Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet, Nutr Res Pract, 4, 191, 10.4162/nrp.2010.4.3.191 Manjunatha, 2007, Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hypercholesterolemic rats, Lipids, 42, 1133, 10.1007/s11745-007-3120-y Martínez-Morúa, 2013, Curcumin decreases oxidative stress in mitochondria isolated from liver and kidneys of high-fat diet-induced obese mice, J Asian Nat Prod Res, 15, 905, 10.1080/10286020.2013.802687 Hu, 2013, Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats, PLoS One, 8, e49976, 10.1371/journal.pone.0049976 Alwi, 2008, The effect of curcumin on lipid level in patients with acute coronary syndrome, Acta Med Indones, 40, 201 Gupta, 2013, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J, 15, 195, 10.1208/s12248-012-9432-8 Sahebkar, 2013, A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels, Clin Nutr